SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- Organovo
Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional
biology company focused on delivering breakthrough 3D bioprinting
technology, announced today that Gregory T.
Lucier has been appointed as a corporate advisor. In
the role, Mr. Lucier will advise Chief Executive Officer
Keith Murphy and the executive
management team on various corporate issues.
"As Organovo moves towards launch of a major new offering, our
3D Human Liver Tissue, we have been putting the pieces in place to
execute on our opportunity and deliver results to shareholders,"
stated Organovo Chief Executive Officer Keith Murphy. "We have been hiring for key
roles, building the necessary internal processes, and driving our
scientists to finalize the tissue production and testing
protocols. Bringing on someone who can assist the company in
our launch stage and during our commercial growth is
critical. Given his tremendous track record of success at
Life Technologies, no one is better for this role than Greg Lucier."
"I'm pleased to be asked to help the executive management of
Organovo deliver on the promise of three dimensional bioprinting,"
said Greg Lucier. "As I have
learned more about Organovo's team and technology, it's clear there
is a compelling opportunity to advance their early scientific
performance into strong commercial wins. I look forward to
using my leadership experience, strategic thinking in the life
sciences industry, and track record bringing biomedical commercial
solutions to market, to help guide the company in its next
phase."
Mr. Lucier was formerly Chairman and CEO of Life Technologies, a
global life sciences company acquired by Thermo Fisher Scientific
for $15.6.billion in 2014. During Mr.
Lucier's 11-year tenure at Life Technologies, he led the company
from a small start-up known as Invitrogen in 2003, directed the
acquisition and merger of Invitrogen with Applied Biosystems in
2008 into the renamed Life Technologies, and then transformed the
organization by 2013 into a global, world-leading biotechnology
firm with 50,000 products, 12,000 employees and nearly $4 billion in sales in more than 180 countries.
Serving in his leadership role, Mr. Lucier was responsible for
fostering a culture of excellence at Life Technologies, and applied
his more than 25 years of strategic management experience to help
champion an era of personalized medicine.
Prior to his tenure at Life Technologies, Mr. Lucier was a
corporate officer of General Electric Company where he served in a
variety of leadership roles. Mr. Lucier received a bachelor's
degree in engineering with honors from Pennsylvania State University, and an MBA from
Harvard Business School. He serves on
the boards of NuVasive Corporation, RainTree Oncology Services,
CareFusion, and is board chairman for Sanford Burnham Medical
Research Institute.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional
human tissues for medical research and therapeutic applications.
The Company is collaborating with pharmaceutical and academic
partners to develop human biological disease models in three
dimensions. These 3D human tissues have the potential to accelerate
the drug discovery process, enabling treatments to be developed
faster and at lower cost. The company plans to market the first
product of a planned portfolio offering, a 3D Human Liver Tissue
for use in Toxicology and other preclinical drug testing prior to
the end of 2014, and remains on track to bring this breakthrough
technology to customers. In addition to numerous scientific
publications, the Company's technology has been featured
in The Wall Street Journal, Time Magazine, The Economist,
and numerous others. Organovo is changing the shape of
medical research and practice. Learn more at www.organovo.com
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the market acceptance of the Company's
products; and the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in our filings with the SEC, including our
annual report on Form 10-K filed with
the SEC on June 10, 2014 as well as our other
filings with the Securities and Exchange Commission. You
should not place undue reliance on these forward-looking
statements, which speak only as of the date that they were made.
These cautionary statements should be considered with any written
or oral forward-looking statements that we may issue in the future.
Except as required by applicable law, including the securities laws
of the United States, we do
not intend to update any of the forward-looking statements to
conform these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated
events.
SOURCE Organovo Holdings, Inc.